Studybox Research CLIA Waiver Studies
Point-of-Care HbA1c Test
Accuracy in the hands of untrained intended-use operators at waived sites.
Studybox
CLIA Waiver Studies
HbA1c is one of the few analytes where a global standardization program, NGSP, effectively sets the accuracy bar for every method. A point-of-care device is compared to an NGSP-traceable laboratory method, and its total error, bias plus imprecision, is judged against expectations that have tightened over time. Waived HbA1c devices have historically been limited to monitoring known diabetes; a diagnostic claim requires demonstrating accuracy and precision near the diagnostic thresholds in untrained hands, and few devices have achieved it in waived settings.
The known weakness of waived HbA1c testing is precision. Independent evaluations of point-of-care HbA1c analyzers have found that some devices fall short of laboratory precision in routine use, and that sites run by untrained operators show more variability than the manufacturer's analytical studies. A waiver study for HbA1c therefore has to show that imprecision at waived sites, with fingerstick sampling by untrained operators, stays within limits that keep the result clinically useful at decision thresholds.
- Analyte
- Hemoglobin A1c (glycated hemoglobin), reported as % HbA1c (NGSP) and mmol/mol (IFCC)
- Therapeutic area
- Cardiovascular Disease
- Specimens
- Capillary Fingerstick Blood, Venous Whole Blood
- Intended-use settings
- urgent care, physician office, pharmacy, hospital POC
- Operators
- Medical assistants, nurses and pharmacists in waived settings; laboratory staff for moderate-complexity claims.
- Comparator
- Typically an NGSP-certified laboratory HbA1c method (HPLC or similar) traceable to the NGSP secondary reference laboratory network, run on paired venous blood.
CLIA Waiver Studies specifics
What Changes for This Assay on This Pathway.
- Precision at waived sites by untrained operators is the central endpoint; the waiver study typically runs a multi-site, multi-day precision protocol with fingerstick samples in addition to the method comparison.
- Fingerstick technique (squeezing, inadequate volume, air bubbles in the capillary collector) is the realistic error source, and flex studies typically stress sample volume, time from collection to analysis, cartridge temperature equilibration and ambient temperature.
- Monitoring-only waived claims have a long precedent; a waived diagnostic claim is a higher bar and should be discussed with FDA before the protocol is finalized.
Endpoints the study must support
- Method comparison bias (regression and difference plots) against the NGSP-traceable comparator across the measuring range, with attention to the diagnostic decision thresholds
- Imprecision (repeatability, within-site and between-site) at low, decision-threshold and high HbA1c levels
- Agreement between capillary fingerstick and venous whole blood on the device
- Interference from common hemoglobin variants (HbS, HbC, HbE, HbD) and elevated HbF
Enrollment realities
Driven by coverage of the HbA1c range rather than subject count; sites must deliberately recruit high values, and a diagnostic claim needs density near the thresholds. Precision arms add repeat visits or multiple fingersticks per subject.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Waiver evidence depends on genuine intended-use operators in genuine waived settings. Our network of 100+ pre-qualified urgent care, physician office, and point-of-care sites already runs IVD protocols, so operator recruitment and site activation don't start from zero. How we run clia waiver studies →
Same assay, other pathways
Relevant FDA guidance
FAQ
Point-of-Care HbA1c Test Study Questions.
01 Who operates the point-of-care hba1c test in a clia waiver studies study?
Medical assistants, nurses and pharmacists in waived settings; laboratory staff for moderate-complexity claims.
02 What is the comparator for a point-of-care hba1c test study?
Typically an NGSP-certified laboratory HbA1c method (HPLC or similar) traceable to the NGSP secondary reference laboratory network, run on paired venous blood.
03 What drives enrollment for a point-of-care hba1c test study?
Driven by coverage of the HbA1c range rather than subject count; sites must deliberately recruit high values, and a diagnostic claim needs density near the thresholds. Precision arms add repeat visits or multiple fingersticks per subject.
Let's talk IVD research
Planning a point-of-care hba1c test study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the clia waiver studies pathway.